Addus HomeCare Corporation

How this company captures the theme economics

Competitive position

Addus is among the largest personal-care providers in the United States, operating in 23 states through approximately 262 offices and serving roughly 107,000 discrete consumers as of December 31, 2025. Scale is a meaningful advantage in a fragmented, locally licensed Medicaid market: Illinois is its largest state market and Texas became its second-largest after the acquisition of Gentiva's personal care operations. Branch density, established managed-care and state Medicaid relationships, and the back-office scale needed to comply with home- and community-based services (HCBS) rules create barriers relative to small local operators.

Scarce assets

State licensure and long-standing Medicaid provider agreements across 23 states; local branch density and a recruited caregiver network supporting roughly 107,000 consumers; managed-care organization (MCO) contracts; and the administrative infrastructure required to manage the HCBS 80/20 payment rule at scale. These are difficult and slow to replicate market by market, which underpins the company's acquisition-led consolidation strategy.

Products, segments, and customers

Three segments: Personal Care (non-medical assistance with activities of daily living for the elderly, chronically ill or disabled at risk of institutionalization; about 76.5% of revenue on a Q1 2025 basis), Hospice (about 18.2%) and Home Health (about 5.3%). Payers are primarily state Medicaid programs for personal care, plus Medicare and managed care for hospice and home health. Operations span 23 states; headquarters is in Frisco, Texas; the company has provided home care since 1979.

Theme capture

Addus captures aging-in-place economics directly: it is paid, predominantly by Medicaid HCBS programs, to keep elderly and disabled individuals in their own homes as a lower-cost alternative to nursing-facility or institutional care. Demand is supported by growth in the 65-plus and 85-plus population and by payer and consumer preference for care at home, while the company also benefits from consolidating a fragmented provider base and from state rate actions that lift reimbursement.

What must be true

1. State Medicaid reimbursement rate increases keep pace with caregiver wage inflation and rising minimum wages, preserving the spread available under the HCBS 80/20 rule.
2. The company continues to recruit and retain direct-care workers at scale despite nationwide personal-care-attendant and direct-support-professional shortages.
3. Acquisitions such as Gentiva's personal care operations are integrated without material margin erosion, and leverage taken on for deals remains serviceable.

Identifiable catalysts

• State budget rate actions, e.g., Illinois' FY2026 budget raising the base in-home care reimbursement rate 3.9% to $30.80 per hour to support an $18.75 minimum wage for direct care workers.
• Further tuck-in personal-care acquisitions expanding state density.
• Managed-care and value-based contract wins, and continued organic volume growth in personal care.

Where the evidence lands

On the SEC-verified FY2025 evidence available, Addus HomeCare is a scaled, cash-generative market leader with disclosed, direct exposure to the aging-in-place theme and a demographically supported, largely non-discretionary demand base; profitability (gross profit $461.9M, operating income $138.6M) and cash conversion (free cash flow ~$103.8M on $7.7M capex) are sound. The decisive analytical questions are whether Medicaid rate adequacy and caregiver labor supply sustain unit economics under the 80/20 rule and whether acquisition-driven leverage remains serviceable. Because the provided dossier omits revenue, margins, and all balance-sheet items, leverage, liquidity and valuation cannot be assessed here, so a complete risk/return judgment requires the missing balance-sheet and market data. This is an evidence assessment, not trading advice.

Next diligence

1. Obtain FY2025 balance-sheet figures from the 10-K (cash, total debt, net debt, net-debt-to-EBITDA, interest coverage) to assess post-Gentiva leverage and liquidity.
2. Analyze segment-level margins and organic-versus-acquired growth from the 10-K and quarterly MD&A, and confirm full-year 2025 segment revenue mix.
3. Track state Medicaid rate actions in top markets (Illinois, Texas, New York and others) and quantify HCBS 80/20 rule compliance costs and effective dates.
4. Acquire licensed market data for valuation (EV/EBITDA, free-cash-flow yield) and consensus estimates to complete the return assessment.